Expression of EMP 1, 2, and 3 in Adrenal Cortical Neoplasm and Pheochromocytoma
暂无分享,去创建一个
[1] H. Gogas,et al. Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas , 2023, Oncology research.
[2] Yang Lu,et al. Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work? , 2022, Cancers.
[3] D. Fraker,et al. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems. , 2020, The Journal of clinical endocrinology and metabolism.
[4] J. Koo,et al. Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors , 2020, PloS one.
[5] Hongyu Yang,et al. High expression of EMP1 predicts a poor prognosis and correlates with immune infiltrates in bladder urothelial carcinoma , 2020, Oncology letters.
[6] S. Puglisi,et al. New perspectives for mitotane treatment of adrenocortical carcinoma. , 2020, Best practice & research. Clinical endocrinology & metabolism.
[7] J. Phay,et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine and Head and Neck Disease Site Working Group, Part 2 of 2: Perioperative Management and Outcomes of Pheochromocytoma and Paraganglioma , 2020, Annals of Surgical Oncology.
[8] M. Berger,et al. PD-1 Blockade in Advanced Adrenocortical Carcinoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Abdulkadir,et al. Nivolumab in metastatic adrenocortical carcinoma: results of a phase II trial. , 2019, The Journal of clinical endocrinology and metabolism.
[10] Youxin Zhou,et al. EMP1 regulates cell proliferation, migration, and stemness in gliomas through PI3K‐AKT signaling and CD44 , 2019, Journal of cellular biochemistry.
[11] Jeffrey E. Lee,et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma , 2019, Journal of Immunotherapy for Cancer.
[12] Wenjing Zhou,et al. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway , 2019, Oncology reports.
[13] L. Brunaud,et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas , 2019, Virchows Archiv.
[14] T. Giordano,et al. Somatic mutations in adrenocortical carcinoma with hyperaldosteronism. , 2018, Endocrine-related cancer.
[15] R. Claus,et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial , 2018, Journal of Immunotherapy for Cancer.
[16] Eric Baudin,et al. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. , 2018, European journal of endocrinology.
[17] A. Kawauchi,et al. Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1 , 2018, Oncogene.
[18] L. Erickson. Challenges in surgical pathology of adrenocortical tumours , 2018, Histopathology.
[19] K. Rajapakshe,et al. ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells , 2018, Investigative ophthalmology & visual science.
[20] Seung Hun Lee,et al. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma , 2017, PloS one.
[21] N. Chow,et al. EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer. , 2017, Biochimica et biophysica acta. Reviews on cancer.
[22] Ming-zi Han,et al. EMP3 is induced by TWIST1/2 and regulates epithelial-to-mesenchymal transition of gastric cancer cells , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[23] M. Habra,et al. Update on adrenocortical carcinoma management and future directions , 2017, Current opinion in endocrinology, diabetes, and obesity.
[24] A. Lam. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours , 2017, Endocrine Pathology.
[25] L. Goodglick,et al. EMP2 is a novel therapeutic target for endometrial cancer stem cells , 2017, Oncogene.
[26] B. Khoo,et al. Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas , 2017, Journal of surgical oncology.
[27] P. Zhang,et al. EMP2 re-expression inhibits growth and enhances radiosensitivity in nasopharyngeal carcinoma , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[28] A. Tabarin,et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.
[29] O. Dekkers,et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. , 2016, European journal of endocrinology.
[30] Weiqing Wang,et al. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma , 2016, Oncotarget.
[31] Shun-Fa Yang,et al. Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway , 2015, Oncotarget.
[32] Yan-Ze Jin,et al. Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma , 2015, Journal of pathology and translational medicine.
[33] T. Choueiri,et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. , 2015, The Lancet. Oncology.
[34] C. Haglund,et al. Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas. , 2015, Human pathology.
[35] H. Ahmed,et al. Immunohistochemical expression of cytokeratins and epithelial membrane protein 2 in nasopharyngeal carcinoma and its potential implications. , 2015, Asian Pacific journal of cancer prevention : APJCP.
[36] M. Papotti,et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. , 2015, The Journal of clinical endocrinology and metabolism.
[37] Gang Zhao,et al. Association of EMP1 with gastric carcinoma invasion, survival and prognosis. , 2014, International journal of oncology.
[38] M. Papotti,et al. CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma , 2014, PloS one.
[39] M. Lai,et al. Potential significance of EMP3 in patients with upper urinary tract urothelial carcinoma: crosstalk with ErbB2-PI3K-Akt pathway. , 2014, The Journal of urology.
[40] W. Young,et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.
[41] S. Ito,et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. , 2014, Endocrine-related cancer.
[42] Wan-ning Hu,et al. Epithelial membrane protein 1 negatively regulates cell growth and metastasis in colorectal carcinoma. , 2014, World journal of gastroenterology.
[43] Y. Lu,et al. EMP1 inhibits nasopharyngeal cancer cell growth and metastasis through induction apoptosis and angiogenesis , 2014, Tumor Biology.
[44] Y. Wang,et al. EMP1 regulates caspase-9 and VEGFC expression and suppresses prostate cancer cell proliferation and invasion , 2014, Tumor Biology.
[45] M. D. Boer,et al. EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion , 2014, Leukemia.
[46] Jonathan Braun,et al. Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer , 2014, Molecular Cancer Therapeutics.
[47] Y. Lu,et al. EMP1, a member of a new family of antiproliferative genes in breast carcinoma , 2014, Tumor Biology.
[48] S. Pittaluga,et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. , 2014, The Journal of clinical endocrinology and metabolism.
[49] C. Wan,et al. Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. , 2013, Experimental and molecular pathology.
[50] C. Chai,et al. Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract. , 2013, The American journal of pathology.
[51] S. Sidhu,et al. Current management options for recurrent adrenocortical carcinoma , 2013, OncoTargets and therapy.
[52] H X Chen,et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma , 2013, British Journal of Cancer.
[53] L. Goodglick,et al. EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF , 2013, Oncogene.
[54] E. Leich,et al. Low SGK1 Expression in Human Adrenocortical Tumors Is Associated with ACTH-Independent Glucocorticoid Secretion and Poor Prognosis , 2012, The Journal of clinical endocrinology and metabolism.
[55] E. Baudin,et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. , 2012, The Journal of clinical endocrinology and metabolism.
[56] P. Argani,et al. Immunohistochemical evidence of dysregulation of the mammalian target of rapamycin pathway in primary and metastatic pheochromocytomas. , 2012, Urology.
[57] G. Scagliotti,et al. Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer , 2012, Clinical Cancer Research.
[58] Wen-Ren Wu,et al. Loss of epithelial membrane protein-2 expression confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study , 2012, BMJ Open.
[59] M. Papotti,et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. , 2012, European journal of endocrinology.
[60] K. Bussey,et al. Targeted Therapies for Adrenocortical Carcinoma: IGF and Beyond , 2011, Hormones & cancer.
[61] L. Goodglick,et al. Epithelial Membrane Protein-2 Promotes Endometrial Tumor Formation through Activation of FAK and Src , 2011, PloS one.
[62] P. Adam,et al. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome , 2010, Modern Pathology.
[63] J. Bertherat,et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. , 2010, Cancer research.
[64] S. Horvath,et al. Epithelial membrane protein‐2 expression is an early predictor of endometrial cancer development , 2010, Cancer.
[65] F. Beuschlein,et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. , 2010, The Journal of clinical endocrinology and metabolism.
[66] L. Goodglick,et al. Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer , 2010, Clinical Cancer Research.
[67] M. Papotti,et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification , 2009, Histopathology.
[68] Herb Chen,et al. Inhibition of the PI3K Pathway Suppresses Hormonal Secretion and Limits Growth in Pheochromocytoma Cells , 2009, World Journal of Surgery.
[69] K. Tanimoto,et al. EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma. , 2009, Cancer letters.
[70] Jinming Yu,et al. EMP3 Overexpression in Primary Breast Carcinomas is not Associated with Epigenetic Aberrations , 2009, Journal of Korean medical science.
[71] A. Wu,et al. Diabodies Targeting Epithelial Membrane Protein 2 Reduce Tumorigenicity of Human Endometrial Cancer Cell Lines , 2008, Clinical Cancer Research.
[72] H. Kuo,et al. The Evolving Transcriptome of Head and Neck Squamous Cell Carcinoma: A Systematic Review , 2008, PloS one.
[73] H. Neumann,et al. Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma , 2008, Endocrine-related cancer.
[74] G. Turashvili,et al. Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas. , 2007, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[75] D. Seligson,et al. Expression of epithelial membrane protein‐2 is associated with endometrial adenocarcinoma of unfavorable outcome , 2006, Cancer.
[76] Karel Pacak,et al. Phaeochromocytoma , 2005, The Lancet.
[77] S. Shak,et al. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[78] C. Moskaluk,et al. Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. , 2005, The American journal of pathology.
[79] P. Adam,et al. AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors. , 2005, The Journal of clinical endocrinology and metabolism.
[80] Miguel Alaminos,et al. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. , 2005, Cancer research.
[81] Stuart M. Brown,et al. Selection and validation of differentially expressed genes in head and neck cancer , 2004, Cellular and Molecular Life Sciences CMLS.
[82] R. Zeillinger,et al. Identification of Genes Associated with the Invasive Status of Human Mammary Carcinoma Cell Lines by Transcriptional Profiling , 2003, Tumor Biology.
[83] Allison Jones,et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells , 2003, Oncogene.
[84] L. Thompson. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases , 2002, The American journal of surgical pathology.
[85] L. del Peso,et al. Hypoxia Induces the Activation of the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway in PC12 Cells , 2001, The Journal of Biological Chemistry.
[86] W. Gerald,et al. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[87] H. Aburatani,et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. , 2001, Cancer research.
[88] U. Suter,et al. Embryonic expression of epithelial membrane protein 1 in early neurons. , 1999, Brain research. Developmental brain research.
[89] B. Scheithauer,et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.
[90] N. Benvenisty,et al. Chromosomal mapping of Tmp (Emp1), Xmp (Emp2), and Ymp (Emp3), genes encoding membrane proteins related to Pmp22. , 1998, Genomics.
[91] U. Suter,et al. Identification and characterization of a cDNA and the structural gene encoding the mouse epithelial membrane protein-1. , 1996, Genomics.
[92] G. Cooper,et al. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. , 1995, Science.
[93] P. Unger,et al. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. , 1991, Archives of pathology & laboratory medicine.
[94] E. Corssmit,et al. Malignant pheochromocytoma and paraganglioma: management options. , 2019, Current opinion in oncology.
[95] A. Ichihara,et al. Combination Chemotherapy with Cyclophosphamide, Vincristine, and Dacarbazine in Patients with Malignant Pheochromocytoma and Paraganglioma , 2013, Hormones and Cancer.
[96] J. 晶,et al. EMP-1 promotes tumorigenesis of NSCLC through PI3K/AKT pathway , 2012, Journal of Huazhong University of Science and Technology [Medical Sciences].
[97] R. Kuick,et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.
[98] E. Baudin,et al. Prognostic parameters of metastatic adrenocortical carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.
[99] P. Devos,et al. A Clinicopathologic and Immunohistochemical Study of 49 Adrenocortical Tumors , 2002 .